| Altisource Portfolio Solutions SA |
43.34%4,954,624 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 23, 2026
|
Nov 14, 2023 |
Decreased Nov 13, 2026 |
— |
Decreased |
13F: none stated |
| Aeon Biopharma Inc. |
16.73%4,400,000 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 11, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| TELA Bio, Inc. |
14.58%6,545,596 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026
|
Nov 10, 2022 |
Decreased Nov 13, 2026 |
▼ 11.68 pts |
Decreased |
13F: none stated |
| Dariohealth Corp. |
9.98%978,340 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026
|
Feb 14, 2019 |
Decreased Nov 13, 2026 |
▼ 2.48 pts |
Decreased |
13F: none stated |
| Eloxx Pharmaceuticals, Inc. |
9.91%400,000 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 7, 2026
|
Aug 16, 2021 |
Decreased Nov 13, 2026 |
▼ 9.91 pts |
Decreased |
13F: none stated |
| ADC Therapeutics SA |
9.85%12,576,184 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 3, 2026
|
Feb 14, 2023 |
Decreased Nov 13, 2026 |
▼ 9.46 pts |
Decreased |
13F: none stated |
| Bioventus Inc. |
9.54%6,420,884 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Mar 28, 2026
|
Nov 10, 2022 |
Decreased Nov 13, 2026 |
▼ 8.29 pts |
Decreased |
13F: none stated |
| Abeona Therapeutics Inc. |
9.46%5,410,643 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 10, 2026
|
Feb 14, 2023 |
Decreased Nov 13, 2026 |
▼ 8.50 pts |
Decreased |
13F: none stated |
| Evolus Inc. |
9.43%6,244,690 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
Nov 14, 2023 |
Decreased Nov 13, 2026 |
▼ 7.53 pts |
Decreased |
13F: none stated |
| The Hain Celestial Group, Inc. |
9.37%8,528,789 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 20, 2026
|
Aug 14, 2025 |
Decreased Nov 13, 2026 |
▼ 9.53 pts |
Decreased |
13F: none stated |
| Fossil Group, Inc. |
9.31%5,505,128 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026
|
Aug 14, 2023 |
Decreased Nov 13, 2026 |
▼ 9.31 pts |
Decreased |
13F: none stated |
| Noodles & Company |
9.29%554,246 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Jul 21, 2026
|
Aug 14, 2023 |
Decreased Nov 13, 2026 |
▼ 9.27 pts |
Decreased |
13F: none stated |
| Jack in the Box Inc. |
9.02%1,730,659 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026
|
Aug 14, 2025 |
Decreased Nov 13, 2026 |
▼ 9.00 pts |
Decreased |
13F: none stated |
| Fulcrum Therapeutics, Inc. |
8.62%6,575,352 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Jul 23, 2026
|
Feb 14, 2023 |
Decreased Nov 13, 2026 |
▼ 5.73 pts |
Decreased |
13F: none stated |
| Destination XL Group, Inc. |
8.40%4,658,915 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Sep 3, 2026
|
Aug 14, 2025 |
Decreased Nov 13, 2026 |
▼ 6.58 pts |
Decreased |
13F: none stated |
| Gogo Inc. |
8.27%11,214,792 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
Nov 14, 2024 |
Decreased Nov 13, 2026 |
▼ 4.57 pts |
Decreased |
13F: none stated |
| Apyx Medical Corporation |
7.94%3,343,353 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 4, 2026
|
Feb 14, 2025 |
Decreased Nov 13, 2026 |
▼ 7.59 pts |
Decreased |
13F: none stated |
| Keros Therapeutics, Inc. |
7.59%1,490,051 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
Aug 14, 2020 |
Decreased Nov 13, 2026 |
▼ 6.63 pts |
Decreased |
13F: none stated |
| Elutia Inc. |
7.41%3,184,947 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Mar 31, 2026
|
Nov 14, 2023 |
Decreased Nov 13, 2026 |
▼ 7.41 pts |
Decreased |
13F: none stated |
| InspireMD, Inc. |
7.26%3,376,484 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 14, 2026
|
Aug 14, 2023 |
Decreased Nov 13, 2026 |
▼ 7.26 pts |
Decreased |
13F: none stated |
| The ONE Group Hospitality, Inc. |
6.70%2,139,182 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 31, 2026
|
May 15, 2024 |
Decreased Nov 13, 2026 |
▼ 6.69 pts |
Decreased |
13F: none stated |
| DHI Group, Inc. |
5.87%2,491,945 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
May 15, 2018 |
Decreased Nov 13, 2026 |
▼ 5.07 pts |
Decreased |
13F: none stated |
| Opus Genetics, Inc. |
5.49%4,569,528 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 3, 2026
|
May 15, 2025 |
Decreased Nov 13, 2026 |
▼ 1.87 pts |
Decreased |
13F: none stated |
| eHealth, Inc. |
5.44%1,761,441 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
Aug 14, 2020 |
Decreased Nov 13, 2026 |
▼ 5.55 pts |
Decreased |
13F: none stated |
| USANA Health Sciences, Inc. |
5.35%988,543 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026
|
Feb 13, 2026 |
Decreased Nov 13, 2026 |
▼ 3.42 pts |
Decreased |
13F: none stated |
| Unicycive Therapeutics Inc. |
5.03%1,401,448 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 12, 2026
|
Nov 15, 2021 |
Decreased Nov 13, 2026 |
▼ 5.03 pts |
Decreased |
13F: none stated |
| Titan Machinery Inc. |
4.83%1,137,589 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 31, 2026
|
Nov 14, 2024 |
Decreased Nov 13, 2026 |
▼ 4.89 pts |
Decreased |
13F: none stated |
| Benitec Biopharma Inc. |
4.81%1,677,567 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Sep 4, 2026
|
Aug 14, 2024 |
Decreased Nov 13, 2026 |
▼ 3.86 pts |
Decreased |
13F: none stated |
| MiMedx Group, Inc. |
4.74%6,910,564 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 22, 2026
|
Feb 14, 2023 |
Decreased Nov 13, 2026 |
▼ 1.81 pts |
Decreased |
13F: none stated |
| Korro Bio, Inc. |
4.72%680,246 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 4, 2026
|
Feb 13, 2026 |
Decreased Nov 13, 2026 |
▼ 4.44 pts |
Decreased |
13F: none stated |
| Fractyl Health, Inc. |
4.70%7,458,269 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 1, 2026
|
Nov 14, 2025 |
Decreased Nov 13, 2026 |
▼ 9.53 pts |
Decreased |
13F: none stated |
| Curis, Inc. |
4.49%93,824 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026
|
Feb 16, 2021 |
Decreased Nov 13, 2026 |
— |
Decreased |
13F: none stated |
| Passage Bio Inc. |
3.96%127,370 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| Traeger, Inc. |
3.93%109,266 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 7, 2026
|
May 15, 2026 |
Decreased Nov 13, 2026 |
▼ 2.03 pts |
Decreased |
13F: none stated |
| Gaia, Inc. |
3.90%974,138 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Mar 31, 2026
|
May 15, 2018 |
Decreased Nov 13, 2026 |
▼ 3.42 pts |
Decreased |
13F: none stated |
| Avalo Therapeutics, Inc. |
3.70%2,142,308 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026
|
Nov 15, 2021 |
Decreased Nov 13, 2026 |
▼ 3.24 pts |
Decreased |
13F: none stated |
| Aura Biosciences, Inc. |
3.67%3,807,300 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 6, 2026
|
Feb 14, 2022 |
Decreased Nov 13, 2026 |
▼ 2.02 pts |
Decreased |
13F: none stated |
| The Bancorp, Inc. |
3.67%1,465,277 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
Aug 14, 2014 |
Decreased Nov 13, 2026 |
▼ 2.41 pts |
Decreased |
13F: none stated |
| Azitra Inc. |
3.65%2,213,613 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026
|
Aug 14, 2026 |
Decreased Nov 13, 2026 |
▼ 3.65 pts |
Decreased |
13F: none stated |
| Savara Inc. |
3.47%7,137,159 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026
|
Nov 14, 2023 |
Decreased Nov 13, 2026 |
▼ 3.32 pts |
Decreased |
13F: none stated |
| Fox Factory Holding Corp. |
3.35%1,403,584 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Apr 3, 2026
|
Feb 14, 2025 |
Decreased Nov 13, 2026 |
▼ 2.90 pts |
Decreased |
13F: none stated |
| LB Pharmaceuticals Inc |
3.32%1,074,374 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 3, 2026
|
Nov 14, 2025 |
Decreased Nov 13, 2026 |
▼ 3.21 pts |
Decreased |
13F: none stated |
| Rayonier Advanced Materials Inc. |
3.31%2,236,017 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026
|
May 16, 2016 |
Decreased Nov 13, 2026 |
▼ 1.71 pts |
Decreased |
13F: none stated |
| Zevra Therapeutics Inc |
3.30%1,963,096 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
Nov 14, 2023 |
Decreased Nov 13, 2026 |
▼ 2.75 pts |
Decreased |
13F: none stated |
| Eton Pharmaceuticals, Inc. |
3.20%875,507 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 12, 2026
|
Aug 14, 2024 |
Decreased Nov 13, 2026 |
▼ 5.39 pts |
Decreased |
13F: none stated |
| Alector, Inc. |
2.90%4,318,109 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
May 13, 2022 |
Decreased Nov 13, 2026 |
▼ 4.83 pts |
Decreased |
13F: none stated |
| JATT II Acquisition Corp. |
2.88%225,000 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 12, 2026
|
Aug 14, 2026 |
Decreased Nov 13, 2026 |
▼ 2.72 pts |
Decreased |
13F: none stated |
| Anteris Technologies Global Corp. |
2.83%2,759,807 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 10, 2026
|
Feb 14, 2025 |
Decreased Nov 13, 2026 |
▼ 4.11 pts |
Decreased |
13F: none stated |
| JATT III Acquisition Corp |
2.82%250,000 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 12, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| Venu Holding Corp. |
2.75%1,546,705 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 13, 2026
|
May 15, 2026 |
Decreased Nov 13, 2026 |
▼ 2.75 pts |
Decreased |
13F: none stated |
| Alta Equipment Group Inc. |
2.42%791,839 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 4, 2026
|
May 14, 2020 |
Decreased Nov 13, 2026 |
▼ 2.01 pts |
Decreased |
13F: none stated |
| X4 Pharmaceuticals Inc. |
2.40%2,449,468 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026
|
Nov 14, 2025 |
Decreased Nov 13, 2026 |
▼ 2.54 pts |
Decreased |
13F: none stated |
| Codexis, Inc. |
2.37%2,597,869 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 6, 2026
|
May 15, 2014 |
Decreased Nov 13, 2026 |
▼ 4.25 pts |
Decreased |
13F: none stated |
| Cellectar Biosciences Inc. |
2.33%219,998 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 11, 2026
|
Feb 14, 2024 |
Decreased Nov 13, 2026 |
▼ 2.33 pts |
Decreased |
13F: none stated |
| Ultragenyx Pharmaceutical Inc. |
2.30%2,339,293 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 29, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| Grace Therapeutics, Inc. |
2.26%476,190 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 11, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| Perspective Therapeutics, Inc. |
2.18%2,492,642 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 5, 2026
|
Aug 14, 2026 |
Decreased Nov 13, 2026 |
▼ 1.89 pts |
Decreased |
13F: none stated |
| Geron Corporation |
2.15%13,873,533 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
Nov 14, 2025 |
Decreased Nov 13, 2026 |
▼ 1.65 pts |
Decreased |
13F: none stated |
| Forrester Research, Inc. |
2.13%413,046 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 4, 2026
|
May 15, 2026 |
Decreased Nov 13, 2026 |
▼ 5.74 pts |
Decreased |
13F: none stated |
| Viemed Healthcare, Inc. |
1.89%714,674 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 27, 2026
|
Nov 14, 2019 |
Decreased Nov 13, 2026 |
▼ 1.43 pts |
Decreased |
13F: none stated |
| Immunic, Inc. |
1.84%250,646 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Jul 31, 2026
|
Feb 13, 2026 |
Decreased Nov 13, 2026 |
▼ 1.84 pts |
Decreased |
13F: none stated |
| Herbalife LTD. |
1.76%1,847,165 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 26, 2026
|
May 15, 2025 |
Decreased Nov 13, 2026 |
▼ 0.36 pts |
Decreased |
13F: none stated |
| Entera Bio Ltd. |
1.73%3,004,848 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| Hilton Grand Vacations Inc. |
1.68%1,276,542 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 22, 2026
|
Feb 14, 2023 |
Decreased Nov 13, 2026 |
▼ 0.97 pts |
Decreased |
13F: none stated |
| Aprea Therapeutics, Inc. |
1.66%205,760 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 13, 2026
|
May 15, 2024 |
Decreased Nov 13, 2026 |
▼ 1.66 pts |
Decreased |
13F: none stated |
| Lexeo Therapeutics, Inc. |
1.66%1,300,000 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 7, 2026
|
Feb 13, 2026 |
Decreased Nov 13, 2026 |
▼ 1.66 pts |
Decreased |
13F: none stated |
| Distribution Solutions Group, Inc. |
1.58%733,684 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 31, 2026
|
Aug 14, 2025 |
Decreased Nov 13, 2026 |
▼ 0.55 pts |
Decreased |
13F: none stated |
| Vor Biopharma Inc. |
1.52%931,644 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 26, 2026
|
Aug 14, 2026 |
Decreased Nov 13, 2026 |
▼ 1.34 pts |
Decreased |
13F: none stated |
| Inhibikase Therapeutics, Inc. |
1.48%1,951,863 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of May 1, 2026
|
Feb 14, 2025 |
Decreased Nov 13, 2026 |
▼ 2.61 pts |
Decreased |
13F: none stated |
| Establishment Labs Holdings Inc. |
1.48%440,556 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 5, 2026
|
Nov 14, 2018 |
Decreased Nov 13, 2026 |
▼ 0.78 pts |
Decreased |
13F: none stated |
| Vyne Therapeutics Inc. |
1.47%39,198 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 10, 2026
|
Feb 13, 2026 |
Decreased Nov 13, 2026 |
— |
Decreased |
13F: none stated |
| Sagimet Biosciences Inc. |
1.45%471,831 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Mar 31, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| Reservoir Media, Inc. |
1.44%952,955 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 26, 2026
|
Nov 14, 2023 |
Decreased Nov 13, 2026 |
▼ 1.41 pts |
Decreased |
13F: none stated |
| Jefferson Capital, Inc. |
1.44%825,607 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 13, 2026
|
Aug 14, 2025 |
Decreased Nov 13, 2026 |
▼ 1.17 pts |
Decreased |
13F: none stated |
| Verastem, Inc. |
1.41%1,779,840 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026
|
Aug 14, 2024 |
Decreased Nov 13, 2026 |
▼ 6.50 pts |
Decreased |
13F: none stated |
| Janux Therapeutics, Inc. |
1.40%857,334 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 3, 2026
|
May 15, 2026 |
Decreased Nov 13, 2026 |
▼ 1.25 pts |
Decreased |
13F: none stated |
| Cue Biopharma, Inc. |
1.32%96,049 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 12, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| Industrial Logistics Properties Trust |
1.31%876,153 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 26, 2026
|
May 15, 2023 |
Decreased Nov 13, 2026 |
▼ 2.02 pts |
Decreased |
13F: none stated |
| Attovia Therapeutics, Inc. |
1.23%561,180 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 31, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| ADMA Biologics, Inc. |
1.17%2,590,475 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 30, 2026
|
Aug 14, 2026 |
Decreased Nov 13, 2026 |
▼ 0.94 pts |
Decreased |
13F: none stated |
| Lisata Therapeutics, Inc. |
1.12%101,221 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Aug 6, 2026
|
Nov 13, 2026 |
— |
— |
New |
13F: none stated |
| Service Properties Trust |
1.07%1,386,791 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Nov 2, 2026
|
Feb 14, 2025 |
Decreased Nov 13, 2026 |
▼ 3.04 pts |
Decreased |
13F: none stated |
| Inspire Medical Systems, Inc. |
1.01%293,034 shares |
13F, quarter ended Sep 30, 2026filed Nov 13, 2026; % of shares outstanding as of Oct 28, 2026
|
Aug 14, 2026 |
Decreased Nov 13, 2026 |
▼ 0.85 pts |
Decreased |
13F: none stated |
| Xtant Medical Holdings, Inc. |
49.1%68,394,000 shares |
Schedule 13D/A, filed Aug 5, 2025 |
Apr 17, 2025 |
— |
0.00 pts |
— |
Standard Item 4 language |
| Aytu Biopharma, Inc |
14.4%1,086,812 shares |
Schedule 13D/A, filed Jun 9, 2025 |
Jun 16, 2023 |
— |
▼ 3.80 pts |
— |
Standard Item 4 language |
| Talphera, Inc. |
11.7%1,992,519 shares |
Schedule 13D/A, filed Apr 3, 2025 |
Jan 23, 2024 |
— |
0.00 pts |
— |
Standard Item 4 language |
| Femasys Inc. |
10.0%803,038 shares |
Schedule 13D, filed Aug 17, 2026 |
Aug 17, 2026 |
— |
— |
— |
Standard Item 4 language |
| America'S Car-Mart, Inc. |
7.8%644,686 shares |
Schedule 13D/A, filed Mar 12, 2025 |
Sep 24, 2024 |
Increased Mar 12, 2025 |
▲ 1.10 pts |
— |
Standard Item 4 language |